Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (73)	5/13/2007 1:42:06 PM
From: tuck	Read Replies (1) of 312

[Hep C prophylaxis with a modified adenoviral vaccine] jvi.asm.org Full text freebie. Very early but interesting. The authors worked at this Roman sub of Merck when this work was done, but now have their own start-up, Okairos. Merck kept the rights for HIV. What's interesting is that adenoviral vectors have always looked good in vitro, but when administered to humans they generated an antibody response that rendered them pretty much ineffective after a while. These guys have developed a vector that does not have the binding site to which said antibodies (anti-Ad5 neutralizing antibodies) attach. Worth watching? No patents issued, but probably some applications have been filed. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next